Adgrg7, also known as GPR128, belongs to the Adhesion G protein-coupled receptor (aGPCR) family. aGPCRs play significant roles in neurodevelopment, immune defence, and cancer [1]. However, the physiological role and regulation of Adgrg7 were not fully elucidated until recently [3].

In research, it was found that Adgrg7 expression was upregulated in response to estrogen (E2) in adolescent idiopathic scoliosis (AIS) cells, and its promoter has an ERα response half-site near an SP1 binding site. Mutation of the SP1 site abrogated the response to E2, indicating the essential role of SP1 in Adgrg7 regulation by E2 [3]. In SARS-CoV-2-infected lung adenocarcinoma Calu-3 cells, the mRNA level of Adgrg7 was significantly increased, and downregulating Adgrg7 led to a decrease in SARS-CoV-2 newly released into the culture media and a reduction in its infectivity, suggesting Adgrg7 might play a role during SARS-CoV-2 infection [2]. Also, in breast cancer, high expression of Adgrg7 was significantly correlated with poor overall survival, and in uterine corpus endometrial carcinoma (UCEC), its expression was elevated, and high levels were associated with shorter overall survival and lower relapse-free survival [4,5].

In conclusion, Adgrg7 is an estrogen-responsive gene regulated by ERα and SP1. It may be involved in viral infection, and its abnormal expression is associated with certain cancers. Studies on Adgrg7 help to understand its functions in disease-related biological processes, potentially providing new targets for treatment in related diseases such as SARS-CoV-2-associated illness, breast cancer, and UCEC [2,3,4,5].